secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-062154
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion presents COVALENT-111 data: up to 1.4% placebo-adjusted HbA1c reduction at Week 26 off therapy
--------------------------------------------------------------------------------

- Placebo-adjusted mean HbA1c reduction up to 1.4% at Week 26 after 28-day BMF-219 treatment.
- 100mg and 200mg dose levels selected for expansion phase; 12-week dosing, follow-up to Week 52.
- No serious adverse events or study discontinuations; no symptomatic hypoglycemia.
- Expansion phase enrolling on schedule; initial 26-week data expected 2H24.
- Biomea plans to announce COVALENT-112 T1D update in Q4 2023 earnings release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524062154/0001193125-24-062154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312524062154/d802391d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-062154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer